Jingyuan Fan
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jingyuan Fan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07890636 · Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCRuijin Hospital · not yet recruiting · Lung Neoplasm Malignant · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:37 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 421 citationsRCR 13.2
- 16 citationsRCR 0.5
- Uniportal versus multiportal thoracoscopic lobectomy: Ergonomic evaluation and perioperative outcomes from a randomized and controlled trial.Medicine (Baltimore) · 202013 citationsRCR 1.1
- FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.Clin Cancer Res · 202413 citationsRCR 1.3
- First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.J Immunother Cancer · 202411 citationsRCR 1.4
- Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.Clin Lung Cancer · 20187 citationsRCR 0.2
- Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.Cancer Immunol Immunother · 20247 citationsRCR 0.8
- [Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer].Zhonghua Zhong Liu Za Zhi · 20233 citationsRCR 0.3